Table 5: TNF-inhibitor and placebo effects
for the ACR-50 score according to the statistical random model.
|
TNF-inhibitor |
Prevalence |
95% CI |
Q-het |
Df-het |
p-value het |
I2 |
|
Adalimumab |
0.154 |
0.026; 0.281 |
33.941 |
2 |
0 |
94.11 |
|
Certolizumab |
0.05 |
0.017; 0.084 |
5.562 |
2 |
0.062 |
64.04 |
|
Etanercept |
0.11 |
0.026; 0.195 |
9.604 |
2 |
0.008 |
79.17 |
|
Golimumab |
0.107 |
0.053; 0.161 |
5.878 |
2 |
0.053 |
65.97 |
|
Infliximab |
0.14 |
0.033; 0.246 |
7.074 |
1 |
0.008 |
85.86 |